Biliary Tract Malignancy
Clinical Overview and Novel Detection Method
For information on specimen collection and processing, see Biliary Tract Malignancy by FISH Testing.
Contact Dr. Gores
For questions regarding the management or treatment of a patient with this condition, contact Dr. Gores (Monday-Friday) at 507-284-6488.
Click CC to turn on closed captioning.
Pancreatobiliary tumors such as cholangiocarcinoma (bile duct cancer) or pancreatic cancer often present as biliary tract obstruction or strictures. Bile duct or hepatobiliary brushing specimens obtained during endoscopic retrograde cholangiopancreatography (ERCP) are used to assess affected patients for possible malignancy using cytologic and molecular techniques. We have developed a statistical model that incorporates routine cytology and FISH test results with clinical factors to predict risk of malignancy in an individual patient.
- Gregory Gores, MD, chair of the Division of Gastroenterology and Hepatology and Professor of Medicine and Physiology in the College of Medicine at Mayo Clinic
- Kevin Halling, MD, PhD, vice chair for research and development for the Department of Laboratory Medicine and Pathology and consultant in the Division of Laboratory Genetics at Mayo Clinic in Rochester, Minnesota
- #84357 Biliary Tract Malignancy, Cytology & Molecular Testing
- #19701 Biliary Tract Malignancy, FISH Only
Forward to a Colleague
Share this presentation with:
- Surgical and Cytopathologists
- Interventional Radiologists
- Internal Medicine Physicians
If you have general questions about a Clinical Insight presentation, e-mail